摘要
不同个体对紫杉类药物疗效存在差异,药物遗传学和药物基因组学的快速发展,使得分子标签指导下的个体化的化疗成为可能,本文将对紫杉类药物疗效预测相关的分子标记物作一综述。
出处
《现代肿瘤医学》
CAS
2009年第8期1583-1584,共2页
Journal of Modern Oncology
参考文献16
-
1Rosell R,Felip E.Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer[J].Semin Oncol,2001,28:37-44.
-
2Monzo M,Rosell R,Sanchez J,et al.Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutation[J].J Clin Oncol,1999,17:1786-1793.
-
3Sève P,Mackey J,Isaac S,et al.Class Ⅲ beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel[J].Mol Cancer Ther,2005,4:2001-2007.
-
4Azzoli C,Khokhar N,Chen J,et al.Correlating quantitative gene expression to radiologic response to docetaxel in formalin-fixed paraffin-embedded tumor tissue from patients with metastatic non-small cell lung cancer (NSCLC)[J].Am Soc Clin Oncol,2004,23:7030.
-
5Mozzetti S,Ferlini C,Concolino P,et al.Class Ⅲ beta-tubulin over expression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients[J].Clin Cancer Res,2005,11:298-305.
-
6Tommasi S,Mangia A,Lacalamita R,et al.Cytoskeleton and paclitaxel sensitivity in breast cancer:the role of beta-tubulins[J].Int J Cancer,2007,120:2078-2085.
-
7Sève P,Reiman T,Lai R,et al.Class Ⅲ beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site[J].Cancer Chemother Pharmacol,2007,60:27-34.
-
8Ferrandina G,Zannoni G,Martinelli E,et alClass Ⅲ beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients[J].Clin Cancer Res,2006,12:2774-2779.
-
9Rouzier R,Rajan R,Wagner P,et al.Microtubule-associated protein tau:a marker of paclitaxel sensitivity in breast cancer[J].Proc Natl Acad Sci USA,2005,102:8315-8320.
-
10Andre F,Hatzis C,Anderson K,et al.Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer[J].Clin Cancer Res,2007,13:2061-2067.
同被引文献12
-
1Kim JG,Sohn SK,Chae YS,et al. Muhieenter phase [l study of doeetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric eancer:Daegu Gyeongbuk Oncology Group [J]. BrJ Caneer,2008,98(3)542-546.
-
2Scartozzi M,Galizia E, Verdecchia L,et al. Chemotherapy for ad vanced gastric cancer:across the years for a standard of care[J]. Expert Opin Pharmaeother, 2007,8 (6) : 797-808.
-
3Van CE,Moiseyenko VM, Tjulandin S, et al. Phase Ul study of do cetaxel and eisplatin plus fluorouracil compared with eisphtin and flu orouracil as first-line therapy t'or advanccxt gastric cancer: A report of the V325 study group[J 1- J Clin ( )ncol, 2006,24 (3 l ) : 4991-4997.
-
4Pentheroudakis G, Kalogeras KT,Wirtz RM, et al. Gene expres- sion of estrogen receptor,progesterone receptor and microtubule associated protein Tau in high-risk early breast cancer= a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial[J]. Breast Cancer Res Treat,2009,116(1) =131-143.
-
5Andre F, Hatzis C, Anderson K, et al. Microtubule-associated pro- tein-tau is a bifunctional predictor of endocrine sensitivity and chemo therapy resistance in estrogen receptor-positive breast cancer[J]. Clin Cancer Res,2007,13(7) 12061-2067.
-
6Wagner P,Wang B,Clark E,et al. Microlubute Associated Pro- tein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo[J]. Cell Cycle,2005,4(9)1149-1152.
-
7Rouzier R,Rajan R,Wagner P,et al. Microtubule-associ-ated protein tau:a marker of paclitaxel sensitivity in breast eancer[J]. Proc Natl Acad Sci USA,2005,102(23) :8315-8320.
-
8Mimori K,Sadanaga N, Yoshikawa Y, et al. Reduced tau expres- sion in gastric cancer can identify candidates for successful Pacli- taxe|treatment[J]. BrJ Cancer,2006,94(12):1894 1897.
-
9任峰,叶正宝,彭春伟,燕敏,俞焙秦,陈雪华,张俊,马韬,刘炳亚,朱正纲.Tau基因表达与紫杉醇治疗胃癌敏感性的研究[J].外科理论与实践,2010,15(4):432-437. 被引量：5
-
10张成辉,张敬伟,李明,李长生.FOLFOX4方案联合表柔比星治疗晚期胃癌的临床研究[J].中华肿瘤防治杂志,2010,17(15):1217-1219. 被引量：4
-
1李静,刘晓琴,杨业,柳斌.LncRNA KCNQ1OT1在非小细胞肺癌组织中的表达及其临床意义[J].中国呼吸与危重监护杂志,2016,15(5):453-457. 被引量：7
-
2林华,何小慧,石远凯.头颈部恶性肿瘤的靶向治疗进展[J].癌症进展,2007,5(6):576-581. 被引量：1
-
3殷蓓蓓,梁军.大肠癌化疗疗效及毒性预测分子的研究进展[J].实用肿瘤杂志,2009,24(2):196-200. 被引量：1
-
4徐露娟,钱晓萍,刘宝瑞.吉西他滨个体化治疗疗效相关预测分子的研究进展[J].现代肿瘤医学,2012,20(3):630-633. 被引量：2
-
5菲琳.药物遗传学研究与癌症化疗效果[J].国外医学情报,2002,23(8):22-23.
-
6张潍,张振华,王辉,张伟,刘伟良,王勇.非小细胞肺癌组织miRNA-203表达及其与预后的关系[J].现代肿瘤医学,2016,24(11):1728-1731. 被引量：6
-
7都丽艳,魏芳.骨桥蛋白在卵巢肿瘤中的研究进展[J].现代肿瘤医学,2014,22(5):1209-1212. 被引量：3
-
8魏风华,赵晓东,张毅,何淑蓉,杨丽.铂类联合紫杉醇对晚期卵巢癌一线化疗疗效预测因素的研究[J].中华医学杂志,2007,87(17):1187-1189. 被引量：2
-
9吕俊杰,徐磊,许有涛,邱满堂,杨欣,王洁,尹荣,许林.非小细胞肺癌组织miRNA-221表达及其与预后的关系研究[J].中国肺癌杂志,2014,17(3):221-225. 被引量：19
-
10张柏林,刘海洁,张保宁.乳腺癌化疗药物遗传学研究进展[J].医学研究杂志,2006,35(8):83-84.
